| 臺大學術典藏 |
2022-02-21T23:31:30Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali, Paolo Andrea; Chia-Chi Lin; Carthon, Bradley C.; Bauer, Todd M.; Tucci, Marcello; Italiano, Antoine; Iacovelli, Roberto; Su, Wu Chou; Massard, Christophe; Saleh, Mansoor; Daniele, Gennaro; Greystoke, Alastair; Gutierrez, Martin; Pant, Shubham; YING-CHUN SHEN; Perrino, Matteo; Meng, Robin; Abbadessa, Giovanni; Lee, Helen; Dong, Yingwen; Chiron, Marielle; Wang, Rui; Loumagne, Laure; Lépine, Lucie; De Bono, Johann |
| 臺大學術典藏 |
2022-02-21T02:51:55Z |
Evolution of systemic treatment for advanced hepatocellular carcinoma
|
Wu T.-C.; YING-CHUN SHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
YING-CHUN SHEN; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-06T03:26:51Z |
Targeted Therapy for Hepatocellular Carcinoma
|
CHIUN HSU; Ying-Chun Shen; Ann-Lii Cheng |
| 臺大學術典藏 |
2021-03-09T05:27:30Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Ying-Chun Shen; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:40Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.; Ying-Chun Shen; Yang C.-H.; Yeh K.-H.; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:39Z |
Difference in the incidence trend of nasopharyngeal and oropharyngeal carcinomas in Taiwan: Implication from age-period-cohort analysis
|
Hsu C.; Ying-Chun Shen; Cheng C.-C.; Hong R.-L.; Chang C.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:39Z |
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung
|
Yeh K.-H.; Yeh S.-H.; Wan J.-P.; Ying-Chun Shen; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:39Z |
Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications from age-period-cohort analysis
|
Ying-Chun Shen; Chang C.-J.; Hsu C.; Cheng C.-C.; Chiu C.-F.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:39Z |
Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines
|
Ying-Chun Shen; Hsu C.; Chen J.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:38Z |
Molecular targeted therapy for advanced hepatocellular carcinoma
|
Ying-Chun Shen; Hsu C.; Cheng A.L. |
| 臺大學術典藏 |
2021-03-09T05:18:38Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Ying-Chun Shen; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:38Z |
Sorafenib for the treatment of hepatocellular carcinoma across geographic regions
|
Hsu C.; Ying-Chun Shen; Cheng A.L. |
| 臺大學術典藏 |
2021-03-09T05:18:38Z |
Molecular subtypes of breast cancer emerging in young women in Taiwan: Evidence for more than just westernization as a reason for the disease in Asia
|
Lin C.-H.; Liau J.-Y.; Lu Y.-S.; Huang C.-S.; Lee W.-C.; Kuo K.-T.; Ying-Chun Shen; Kuo S.-H.; Lan C.; Liu J.M.; Kuo W.-H.; Chang K.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:37Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:37Z |
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B
|
Ko B.-S.; Chang T.-C.; Chen C.-H.; Liu C.-C.; Kuo C.-C.; Hsu C.; Ying-Chun Shen; Shen T.-L.; Golubovskaya V.M.; Chang C.-C.; Shyue S.-K.; Liou J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:37Z |
Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design
|
Hsu C.; Ying-Chun Shen; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:36Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:36Z |
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
|
Ying-Chun Shen; Hsu C.; Chen L.-T.; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:36Z |
Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives
|
Ying-Chun Shen; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:35Z |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
|
Hsu C.-Y.; Ying-Chun Shen; Yu C.-W.; Hsu C.; Hu F.-C.; Hsu C.-H.; Chen B.-B.; Wei S.-Y.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2021-03-09T05:18:35Z |
Induction of DNA damage-inducible gene GADD45�] contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Ou D.-L.; Ying-Chun Shen; Yu S.-L.; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression
|
Ying-Chun Shen; Hsu C.; Cheng C.-C.; Hu F.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma
|
Cheng A.-L.; Ying-Chun Shen; Zhu A.X. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
Antiangiogenic strategies for the treatment of hepatocellular carcinoma
|
Hsu C.; Ying-Chun Shen; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:34Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:33Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:33Z |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression
|
Hsu C.; Ying-Chun Shen; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H. |
| 臺大學術典藏 |
2021-03-09T05:18:32Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Ying-Chun Shen; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:32Z |
erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)
|
Hsu C.; Ying-Chun Shen; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; Yeh K.-H. |
| 臺大學術典藏 |
2021-03-09T05:18:32Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Ying-Chun Shen; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; Lin C.-Y.; Liu S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:31Z |
Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): Preclinical activity in the Myc-CaP model
|
Ying-Chun Shen; Ghasemzadeh A.; Kochel C.M.; Nirschl T.R.; Francica B.J.; Lopez-Bujanda Z.A.; Carrera Haro M.A.; Tam A.; Anders R.A.; Selby M.J.; Korman A.J.; Drake C.G. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma
|
Ying-Chun Shen; Hsu C.-L.; Jeng Y.-M.; Ho M.-C.; Ho C.-M.; Yeh C.-P.; Yeh C.-Y.; Hsu M.-C.; Hu R.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-03-09T05:18:29Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
